Skip to main content

Instalimb

HardwareTokyo, JapanFounded 2017· One of 1778 Hardware companies tracked by AMPulse

There are 90 million people in the world who cannot afford prosthetics. Our company is a startup that aims to solve this social problem by developing and manufacturing mass-customized prosthetics (prosthetic legs), each with a unique shape tailored to the individual, using the new technology of '3D printing x AI technology'.

CEO / Founder
Yutaka Tokushima
Team Size
201-500
Stage
Growth Stage
Total Funding
$14.2M
Latest Round
Strategic Investment
Key Investors
Global Brain; UTokyo Innovation Platform; IT-Farm; JIC Venture Growth Investments; Dai-ichi Life Insurance; Darwin Venture Management; Kyocera Ventures; Mizuho Capital; Orthomos Investment; MUFG Capital

Technology & Products

Key Products

3D-printed prosthetic legs and orthotics, utilizing 3D-CAD, 3D printing, and machine learning (AI) technology for mass customization and affordability. Offers an end-to-end digital manufacturing process.

Technological Advantage

AI-driven customization for prosthetics; defensible due to unique technology.

Differentiation

Value Proposition

Providing affordable, mass-customized prosthetics using 3D printing and AI technology to address the unmet needs of 90 million people worldwide.

How They Differentiate

Focus on affordability and mass customization using AI and 3D printing.

Market & Competition

Target Customers

Individuals requiring affordable prosthetic solutions

Industry Verticals

Medical; Healthcare

Competitors

Axiles Bionics, Össur, BionicM

Growth & Milestones

Growth Metrics

Cumulative funding ¥21.3B+ (~$14.2M+) through Series B-ext + subsequent rounds; 6+ countries; 4K+ Global Happiness; 9,000+ 3D prosthetics delivered; ~250 staff globally

Major Milestones

2017-03: Founded (徳島 泰); 2021: Series A; 2024-03: Series B ¥9B; 2025-03: Series B-ext ¥11B (cum ¥21.3B); 2025: UNIDO/JBIC Ukraine projects; 2026-05: Orthomos J-KISS + ALCARE MoU (Japan market); 2026-07: Tokyo SusHi Tech Global 4th cohort

Notable Customers

Jaipur Foot (BMVSS), ALIMCO, VOSAP, Philippine Orthopedic Center (POC), Halychyna Rehabilitation Center (Ukraine/UNIDO)

https://www.instalimb.com

Recent coverage of Instalimb

Why this company matters

AMPulse analysis, not a company disclosure

Instalimb addresses a global access gap in prosthetics by combining AI-driven design with polymer additive manufacturing. While traditional prosthetic fabrication is labor-intensive and costly, Instalimb's end-to-end digital process—spanning 3D-CAD, machine learning, and 3D printing—enables mass customization at a fraction of the price. This positions the company as a low-cost alternative to established players like Össur and Axiles Bionics, particularly in developing markets.

The core technology relies on polymer AM (likely FDM or SLA) to produce prosthetic legs and orthotics tailored to each user's anatomy. AI algorithms automate the customization workflow, reducing the need for manual fitting and enabling rapid production scaling. Instalimb's IP portfolio includes patents related to its AI-driven customization method, though the specific claims remain unverified.

Target customers are individuals in low-resource settings who lack access to affordable prosthetics. Notable partners include Jaipur Foot (BMVSS), ALIMCO, and VOSAP, along with institutional support from UNIDO. The company operates in six countries and reports serving over 2,000 users. Its primary competition comes from BionicM and other bionic-focused startups, though Instalimb differentiates on cost and accessibility rather than advanced biomechatronics.

Instalimb has raised $10.6 million across three rounds from investors including Global Brain, UTokyo Innovation Platform, Kyocera Ventures, and Mizuho Capital. The Series B round in 2025 signals growing investor confidence in the social enterprise model. A key open question is whether the company can maintain quality and durability at scale while keeping prices low enough to serve its target demographic without sustained subsidy.